TLK-286

Claire F. Verschraegen, Harriet O. Smith, Fa Chyi Lee, Cynthia Cathcart, Jeffery P. Norenberg

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Telik Inc is developing TLK-286, a modified glutathione analog prodrug, for the potential treatment of cancer.

Original languageEnglish (US)
Pages (from-to)771-781
Number of pages11
JournalIDrugs
Volume7
Issue number8
StatePublished - Aug 2004
Externally publishedYes

Fingerprint

Prodrugs
Glutathione
Neoplasms
TER 286

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Verschraegen, C. F., Smith, H. O., Lee, F. C., Cathcart, C., & Norenberg, J. P. (2004). TLK-286. IDrugs, 7(8), 771-781.

TLK-286. / Verschraegen, Claire F.; Smith, Harriet O.; Lee, Fa Chyi; Cathcart, Cynthia; Norenberg, Jeffery P.

In: IDrugs, Vol. 7, No. 8, 08.2004, p. 771-781.

Research output: Contribution to journalArticle

Verschraegen, CF, Smith, HO, Lee, FC, Cathcart, C & Norenberg, JP 2004, 'TLK-286', IDrugs, vol. 7, no. 8, pp. 771-781.
Verschraegen CF, Smith HO, Lee FC, Cathcart C, Norenberg JP. TLK-286. IDrugs. 2004 Aug;7(8):771-781.
Verschraegen, Claire F. ; Smith, Harriet O. ; Lee, Fa Chyi ; Cathcart, Cynthia ; Norenberg, Jeffery P. / TLK-286. In: IDrugs. 2004 ; Vol. 7, No. 8. pp. 771-781.
@article{f01807d6e67b433e88381d87a50f03c4,
title = "TLK-286",
abstract = "Telik Inc is developing TLK-286, a modified glutathione analog prodrug, for the potential treatment of cancer.",
author = "Verschraegen, {Claire F.} and Smith, {Harriet O.} and Lee, {Fa Chyi} and Cynthia Cathcart and Norenberg, {Jeffery P.}",
year = "2004",
month = "8",
language = "English (US)",
volume = "7",
pages = "771--781",
journal = "IDrugs : the investigational drugs journal",
issn = "1369-7056",
publisher = "Current Drugs Ltd.",
number = "8",

}

TY - JOUR

T1 - TLK-286

AU - Verschraegen, Claire F.

AU - Smith, Harriet O.

AU - Lee, Fa Chyi

AU - Cathcart, Cynthia

AU - Norenberg, Jeffery P.

PY - 2004/8

Y1 - 2004/8

N2 - Telik Inc is developing TLK-286, a modified glutathione analog prodrug, for the potential treatment of cancer.

AB - Telik Inc is developing TLK-286, a modified glutathione analog prodrug, for the potential treatment of cancer.

UR - http://www.scopus.com/inward/record.url?scp=16544388297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16544388297&partnerID=8YFLogxK

M3 - Article

C2 - 15334311

AN - SCOPUS:16544388297

VL - 7

SP - 771

EP - 781

JO - IDrugs : the investigational drugs journal

JF - IDrugs : the investigational drugs journal

SN - 1369-7056

IS - 8

ER -